Lung cancer is leading cause of cancer death worldwide & lung biopsy is the gold standard method of diagnosis.
Early diagnosis has been proven to save lives making lung biopsy a vital armament in the battle against lung cancer.
Approximately, 1 in 3 patients undergoing a lung biopsy suffer from a collapsed lung, known as pneumothorax.
This dangerous complication converts a routine outpatient procedure to one requiring hospitilisation, for up to a week, for invasive treatment & follow-up.
This results in healthcare costs in excess of $15,000 per patient making it the No. 1 hospital cost & complication post lung biopsy.
Selio Medical adopts an unique approach by providing pneumothorax protection before the biopsy even takes place.
The Selio Sealant System is a single use, prophylactic device, comprising a percutaneous delivery needle together with a novel biodegradable hydrogel sealant.
Our proven patented technology seamlessly integrates with the current standard of care and enables the clinician to pre-seal the access route into the lung before the biopsy.
The Selio Sealant System provides pneumothorax protection for the in-patient, thereby allowing the patient to safely return home on the same day as their procedure. This significantly improves the patient’s quality of care while preventing further treatment and costs.
June 2022: Selio Medical has been awarded €2.5 million funding from the European Innovation Council (EIC) Accelerator programme. This latest funding will support growing the team in Ireland and further technical development as it prepares for market launch. Read More.
March 2022: Ireland’s Health Innovators: Selio Medical is one of the three start-ups making impact internationally. Read More.
November 2021: Delighted to receive the prestigious Rising Star Award at the Ireland-France Business Awards presented by An Taoiseach Micheal Martin and French Minister Franck Riester. Read More.
November 2021: Selio Medical proud to be included in the Sunday Business Post list of 2021 ‘Hot 100 Start-ups’.
August 2021: Selio Medical very proud to welcome a large delegation as part of President Macron visit to Ireland. This delegation included a number of dignitaries including French Finance Minister Bruno Le Maire and Irish Minister for Finance Paschal Donohoe. Read More.
August 2021: Selio Medical delighted to welcome new CEO of Enterprise Ireland Leo Clancy and Chairman of GEC, David Varian to our facility.
August 2020: Selio Medical delighted to welcome Tanaiste Leo Varadkar and Enterprise Ireland CEO Julie Sinnamon, to the new Selio Medical facility in the Guinness Enterprise Centre. Read More.
January 2018: Selio Medical, Headstart/Proof-of-Concept Winner 2017 : EIT Health UK-Ireland @ Oxford University. Read more.
October 2017: Selio Medical, Winner at Medtech Innovator in San Jose, US, out of over 600 medical device start-up companies. Read more.
Setembro 2017: Selio Medical wins Medtech Innovator International Pitch Competition.
September 2017: Selio Medical selected as first international company to take part in prestigious National Science Foundation Icorps accelerator program. Completed in Gerogia Tech, Atlanta 2017. Read more.
August 2017: Selio lung biopsy device exemplifies medtech growth and scale. Colm McGarvey and Garrett Ryan are eliminating collapsed lung complications. Read more.
July 2017: Selio Medical chosen in top 10 of Enterprise Ireland Big Ideas Competition 2017.
May 2017: Selio Medical highlighted as one of 5 Irish big ideas that can transform medical treatment. Read more.
Co-Founders Colm McGarvey & Dr. Garrett Ryan identified this large unmet clinical need during the BioInnovate Fellowship Programme at the National University of Galway (NUIG) & at the University College Cork (UCC). The project then spun-into Trinity College Dublin where it was de-risked with support from Enterprise Ireland.
Selio Medical spun-out of Trinity College Dublin into a new facility located in the heart of Dublin, significantly expanding the team with the support from our international corporate investor, EIT Health and the European Innovation Council (EIC).
Selio Medical continues to develop our platform technology to improve the lives of lung cancer patients worldwide.
Dr. Garrett Ryan
An honest and results focused engineer with extensive experience in the development and commercialisation of medical devices. He has led multiple medical devices from concept to market in the cardiovascular, endo-surgery, urological and respiratory fields. Garrett completed both his undergraduate and PhD training at National University of Ireland, Galway.
An ambitious, dynamic and visionary professional with over 22 years commercial experience, national and international, within the medical device and pharmacy sectors. Colm holds a BSc Degree in Pharmacy from Queens University Belfast and a MSc in Bio-Innovation from University College Cork.